| Autor: |
Michael K, Manion, David M, Hockenbery |
| Rok vydání: |
2003 |
| Předmět: |
|
| Zdroj: |
Cancer biologytherapy. 2(4 Suppl 1) |
| ISSN: |
1538-4047 |
| Popis: |
The BCL-2 family proteins are attractive targets for drug design. As pivotal regulators of apoptotic cell death, the logic of manipulating BCL-2 functions for anti-tumor effects is perhaps the strongest for any of the molecular targets proposed for cancer therapeutics. Moreover, elevated levels of anti-apoptotic proteins have been demonstrated in virtually every type of human cancer. BCL2-specific antisense oligonucleotides have shown broad anti-cancer activities in pre-clinical models and are currently in several phase III trials. Rational drug design to manipulate the functions of these proteins has been hampered by the lack of a clear understanding of biochemical or molecular functions. Initial efforts have been centered on disrupting protein-protein interactions within the BCL-2 homology (BH) family. Substantial progress in this task has been made using molecular modeling and drug leads. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
